<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-24T22:28:29Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/389931" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/389931</identifier><datestamp>2026-08-25T00:41:38Z</datestamp><setSpec>com_1810_221925</setSpec><setSpec>com_1810_34581</setSpec><setSpec>col_1810_224160</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Cytosolic Nucleic Acid Sensing and Senescence in a Patient-Derived Model of Progressive Multiple Sclerosis</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">https://doi.org/10.17863/CAM.121667</dc:identifier>
   <dc:creator>Prasad, Pranathi</dc:creator>
   <uketdterms:advisor>Pluchino, Stefano</uketdterms:advisor>
   <dcterms:abstract>Multiple Sclerosis (MS) is an inflammatory, autoimmune disorder of the central nervous system
(CNS) affecting 2.8 million people worldwide and characterised by an attack by adaptive immune
cells against myelin. For reasons not yet fully understood, most patients eventually transition to a
disease stage known as progressive MS (P-MS), involving a shift from adaptive immune disease
mechanisms to a CNS-compartmentalised innate immune response. During P-MS, the
inflammatory activity of CNS-resident cells is thought to drive axonal degeneration, neuronal loss
and the irreversible accumulation of disability. The treatment options for P-MS are currently
extremely limited.
Ageing and senescence are implicated as critical drivers of disease progression, and cellular
senescence has been observed in immature cells resembling neural stem cells within brain lesions
of patients with P-MS. Prior research demonstrates that directly induced neural stem cells (iNSCs)
derived from patients with P-MS exhibit an inherent senescent phenotype and intrinsic
dysfunctions including heightened inflammation and altered metabolism. However, the precise
mechanisms driving cellular senescence and their contributions to the pathobiological processes
in P-MS remain poorly understood.
Using patient-derived iNSCs as a model for P-MS, my PhD aimed to uncover the mechanisms
underpinning senescence and to study its role in driving pathological changes in the P-MS brain.
In this thesis, I conducted phosphoproteomic analysis and identified key dysregulations in
pathways related to senescence and antiviral responses in patient-derived cells. Using biochemical
assays, I unveiled the accumulation of mitochondria-derived double-stranded RNA (mt-dsRNA)
in the cytosol of P-MS iNSCs, driving activation of the antiviral RIG-I/MDA5-MAVS signalling
pathway. I found this accumulation of mt-dsRNA to be a key driver of senescence, innate immune
activation through the TBK1-IRF3 axis, and the secretion of paracrine inflammatory factors
capable of transferring a reactive, interferon-responsive and disease-associated phenotype to
astrocytes. Notably, interventions inhibiting the sensing of this mt-dsRNA in P-MS iNSCs
attenuated senescence and innate immune activation, while also dampening the spread of pro-
inflammatory responses.
My findings suggest that mt-dsRNA serves as a crucial driver of senescence-associated dysfunction
in a patient stem cell model of P-MS, highlighting the potential contribution of cytosolic nucleic
acid sensing to disease pathobiology and identifying novel therapeutic targets for further
investigation.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2025-05-28</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/389931</dcterms:isReferencedBy>
   <uketdterms:embargotype>embargo</uketdterms:embargotype>
   <uketdterms:embargodate>2027-09-25</uketdterms:embargodate>
   <dc:identifier xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/bitstreams/a0c3f07b-196c-48ca-b850-3b8621534021/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">cd98499ffbe301034988bf8916c396d0</uketdterms:checksum>
   <dcterms:license>https://www.repository.cam.ac.uk/bitstreams/4912e9f5-442e-4a99-aecc-9d5bb807f2a9/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">87eda9de84448d1f82354d60eee3eb5f</uketdterms:checksum>
   <dc:rights>http://purl.org/NET/rdflicense/allrightsreserved</dc:rights>
   <dc:subject>Multiple Sclerosis</dc:subject>
   <dc:subject>Senescence</dc:subject>
   <dc:subject>Neuroinflammation</dc:subject>
   <dc:subject>Progressive Multiple Sclerosis</dc:subject>
   <dc:subject>Cytosolic Nucleic Acids</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>